Jeffrey Zaltzman


Associate Scientist, Li Ka Shing Knowledge Institute


Dr. Jeffrey Zaltzman graduated with both his undergraduate degree and MD from McGill University. He completed a residency in Internal Medicine at the University of Manitoba, in addition to Nephrology and Transplant training at the University of Toronto, where he also received a MSc in Clinical Epidemiology.

Dr. Zaltzman joined the Division of Nephrology at St. Michael’s Hospital in 1993, where played an active role in the resurgence of the kidney transplant program. In 2000, he was appointed as the Director of the Renal Transplant Program. Dr. Zaltzman has also served as the Director of the Internal Medicine Residency Program at St. Michael’s Hospital and has also been involved in research ethics, where he served as the Chair of the Research Ethics Board (REB) from 2000-2002.

He continues to serve as Educational Director of Nephrology at St. Michael’s Hospital. He is the Medical Director of the Diabetes Comprehensive Care Program, in addition to the Chief Medical Officer, Transplant of Trillium Gift of Life. He currently Chairs the Canadian Society of Transplantation Kidney Working group. He was actively involved with the Kidney Foundation of Canada in both the provincial and national levels. His research interests are in the areas of chronic allograft nephropathy, cardiovascular issues, and renal function in transplantation and transplant ethics. He has over 80 peer-reviewed publications.

Please note: Dr. Zaltzman is not taking any summer students in 2018.

Recent Publications

  1. Ho, A, Zaltzman, J, Hare, GMT, Chen, L, Fu, L, Tarlo, SM et al.. Severe and near-fatal anaphylactic reactions triggered by chlorhexidine-coated catheters in patients undergoing renal allograft surgery: a case series. Can J Anaesth. 2019; :. doi: 10.1007/s12630-019-01441-5. PubMed PMID:31264193 .
  2. Prasad, GVR, Beckley, J, Mathur, M, Gunasekaran, M, Nash, MM, Rapi, L et al.. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect. Dis. 2019;19 (1):311. doi: 10.1186/s12879-019-3944-0. PubMed PMID:30953458 PubMed Central PMC6451305.
  3. Zaltzman, J. Ten years of Israel's organ transplant law: is it on the right track?. Isr J Health Policy Res. 2018;7 (1):45. doi: 10.1186/s13584-018-0232-1. PubMed PMID:30068388 PubMed Central PMC6069893.
  4. Rao, V, Dhanani, S, MacLean, J, Payne, C, Paltser, E, Humar, A et al.. Effect of organ donation after circulatory determination of death on number of organ transplants from donors with neurologic determination of death. CMAJ. 2017;189 (38):E1206-E1211. doi: 10.1503/cmaj.161043. PubMed PMID:28947546 PubMed Central PMC5621932.
  5. Misra, P, Kirpalani, A, Leung, G, Vlachou, PA, Lee, JY, Jothy, S et al.. The role of thrombectomy and diffusion-weighted imaging with MRI in post-transplant renal vein thrombosis: a case report. BMC Nephrol. 2017;18 (1):224. doi: 10.1186/s12882-017-0618-2. PubMed PMID:28693502 PubMed Central PMC5504730.
  6. Ribic, CM, Holland, D, Howell, J, Jevnikar, A, Kim, SJ, Knoll, G et al.. Study of Cardiovascular Outcomes in Renal Transplantation: A Prospective, Multicenter Study to Determine the Incidence of Cardiovascular Events in Renal Transplant Recipients in Ontario, Canada. Can J Kidney Health Dis. 2017;4 :2054358117713729. doi: 10.1177/2054358117713729. PubMed PMID:28660072 PubMed Central PMC5476328.
  7. Zaltzman, JS. Is There a Role for mTOR Inhibitors in Renal Transplantation?. Transplantation. 2017;101 (2):228-229. doi: 10.1097/TP.0000000000001541. PubMed PMID:27779576 .
  8. Chen, L, Liberatore, L, Chin, T, Walker, S, Fanous, H, Nash, MM et al.. The Impact of Total Gastrectomy on Pharmacokinetics in Kidney Transplant Immunosuppressive Drug Regimes: A Case Study. Transplantation. 2017;101 (9):2213-2217. doi: 10.1097/TP.0000000000001507. PubMed PMID:27748705 .
  9. Montada-Atin, T, Choi, D, Woo, M, Retnakaran, R, Huang, M, Prasad, GV et al.. Reduction in new-onset diabetes mellitus after renal transplant with erythropoietin-stimulating agents: a retrospective cohort study. Can J Kidney Health Dis. 2016;3 :23. doi: 10.1186/s40697-016-0114-9. PubMed PMID:27119016 PubMed Central PMC4845385.
  10. Prasad, GVR, Ananth, S, Palepu, S, Huang, M, Nash, MM, Zaltzman, JS et al.. Commercial kidney transplantation is an important risk factor in long-term kidney allograft survival. Kidney Int. 2016;89 (5):1119-1124. doi: 10.1016/j.kint.2015.12.047. PubMed PMID:27083285 .
Search PubMed

Affiliations & Other Activities

  • Director, Diabetes Comprehensive Care Program, St. Michael’s Hospital
  • Director, Renal Transplant Program, Division of Nephrology, St.Michael’s Hospital
  • Professor of Medicine, University of Toronto Chief Medical Officer, Trillium Gift of Life